Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Zopiclone
Drug ID BADD_D02397
Description Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.
Indications and Usage For the short-term treatment of insomnia.
Marketing Status approved
ATC Code N05CF01
DrugBank ID DB01198
KEGG ID D01372
MeSH ID C515050
PubChem ID 5735
TTD Drug ID D0ZB7K
NDC Product Code 66639-265; 64330-058; 63190-0030; 65372-1185
UNII 03A5ORL08Q
Synonyms zopiclone | 6-(5-chloro-2-pyridyl)-6,7-dihydro- 7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methyl-1- piperazinecarboxylate | Zop | Zopicalma | zopiclodura | Zopiclon AbZ | Zopiclon AL | Zopiclon AZU | Zopiclon beta | Zopiclon Stada | Zopiclon TAD | zopiclon von ct | Zopiclon-neuraxpharm | Zopiclon-TEVA | Zopitan | Zorclone | Imovane | Ximovan | Zimovane | Limovan | Nu-Zopiclone | Optidorm | ratio-Zopiclone | Zopiclon-ratiopharm | Rhovane | RP 27 267 | Siaten | Somnosan | Zileze | Zimoclone | Zopi-Puren | Zopicalm
Chemical Information
Molecular Formula C17H17ClN6O3
CAS Registry Number 43200-80-2
SMILES CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal adhesions12.02.03.006; 07.07.03.001--Not Available
Abdominal discomfort07.01.06.001--Not Available
Acute hepatic failure09.01.03.001--Not Available
Aggression19.05.01.001--Not Available
Agitation19.06.02.001; 17.02.05.012--
Alcohol poisoning19.07.06.002; 12.03.01.017--Not Available
Amblyopia06.02.01.001--Not Available
Amnesia19.20.01.001; 17.03.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anger19.04.02.001--Not Available
Angioedema23.04.01.001; 10.01.05.009; 22.04.02.008--Not Available
Anterograde amnesia19.20.01.005; 17.03.02.005--Not Available
Anxiety19.06.02.002--
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Breast cancer21.05.01.003; 16.10.01.001--Not Available
Breath odour07.01.06.002--Not Available
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Chills15.05.03.016; 08.01.09.001--
Cholelithiasis09.03.01.002--Not Available
Chromaturia20.02.01.002--
Colitis ulcerative10.02.01.004; 07.08.01.005--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Congenital anomaly03.02.01.001--Not Available
Constipation07.02.02.001--
Coordination abnormal17.02.02.004--Not Available
Dehydration14.05.05.001--
Delirium19.13.02.001--
Delusion19.10.01.001--
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene